What Is Proton Therapy?

Proton therapy is a form of radiation treatment that uses a focused beam of accelerated protons to deliver a concentrated radiation dose to diseased tissue, most commonly a malignant tumor. Unlike conventional photon-based radiotherapy, which deposits energy along the entire path from the skin surface to the target and beyond, protons slow to a stop within the body and release the bulk of their energy at a well-defined depth known as the Bragg peak. By tuning the proton energy, clinicians can align the peak precisely with the tumor volume, reducing the dose absorbed by surrounding healthy tissue and critical structures. Proton therapy draws on accelerator physics, medical physics, nuclear engineering, and radiation biology.

The biological rationale for proton therapy is grounded in the mechanisms of radiation damage to living cells. High-energy charged particles ionize atoms along their path, and this ionization produces free radicals and direct strand breaks in DNA. The spatial distribution of that ionization determines both the tumor control probability and the risk of normal tissue injury. Because proton beams deposit roughly 50% less dose to adjacent normal tissue compared with photon beams of equivalent tumor coverage, the technology is particularly valuable when tumors lie near the brain, spinal cord, optic chiasm, or other sensitive structures.

The Bragg Peak and Dose Delivery

The Bragg peak is the characteristic dose distribution of a heavy charged particle traveling through matter: energy loss per unit path length increases as the particle slows, culminating in a sharp maximum just before the particle stops. In clinical practice, the beam energy is spread over a range of values to cover tumors that are wider than a single Bragg peak. This produces a spread-out Bragg peak (SOBP), where a modulated set of energies fills the tumor volume with a uniform dose plateau. Pencil-beam scanning, a delivery technique in which a narrow proton beam is swept across the tumor layer by layer under magnetic steering, allows each sub-volume to receive an independently specified dose, enabling highly conformal intensity-modulated proton therapy. Clinical outcomes across multiple tumor types reviewed in research published in PMC confirm that this conformal dose delivery translates to measurable reductions in normal-tissue toxicity.

Accelerator Technology and Beam Delivery

Most proton therapy centers use cyclotrons or synchrotrons to accelerate protons to energies between 70 and 250 MeV, sufficient to reach depths of 4 to 38 centimeters in tissue. Cyclotrons, particularly isochronous superconducting designs, are favored for their compact footprint and continuous beam output. Synchrotrons offer adjustable energy extraction, which simplifies pencil-beam scanning without the need for energy-degrading absorbers. Gantries, which rotate the beam delivery nozzle around the patient while the patient remains stationary on a couch, allow beams to be directed from multiple angles. The National Association for Proton Therapy tracks the global growth of clinical proton centers, which numbered over 120 operating facilities worldwide as of 2025.

Biological Effects of Radiation at the Bragg Peak

The relative biological effectiveness (RBE) of proton beams is approximately 1.1 compared to photon radiation for most tissues, meaning protons produce about 10% more biological damage per unit of absorbed dose. However, RBE varies with proton energy, the position within the SOBP, and the tissue type, and active research aims to refine RBE models used in treatment planning. Clinical trials coordinated by the Proton Collaborative Group are accumulating prospective data on proton versus photon outcomes across multiple cancer sites to guide future dose prescription practices.

Applications

Proton therapy has applications in a wide range of clinical and research contexts, including:

• Pediatric cancer treatment, where reducing scattered radiation lowers the risk of secondary cancers and growth disruption
• Central nervous system tumors, including brain and spinal tumors near eloquent structures
• Head and neck cancers, where sparing the salivary glands and brainstem improves quality of life
• Prostate cancer and lung cancer, the subjects of active randomized clinical trials comparing proton and photon outcomes
• Ocular melanoma treatment using dedicated low-energy proton beams